PTC Therapeutics | PTCT - Interest Expense On Debt


PTC Therapeutics reported $3.25B in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Alnylam Pharmaceuticals USD 82.05M 12.76M Jun/2026
Amgen USD 95.64B 94.98B Jun/2026
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Cytokinetics USD 33.34M 3M Mar/2026
Daiichi Sankyo JPY 3.57B 1.4B Mar/2026
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Gilead Sciences USD 247M 7M Jun/2026
Incyte USD 582K 13K Jun/2026
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
Novartis USD 462M 119M Jun/2026
Pfizer USD 667M 4M Jun/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 21.71M 869K Mar/2026
TG Therapeutics USD 16.57M 8.91M Jun/2026
Ultragenyx Pharmaceutical USD 22M 1000K Jun/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Xencor USD 4.7M 2.65M Mar/2026